Heron Therapeutics annual gross margin
2022
2023
2024
2025
Heron Therapeutics's gross margin was 73.31% for fiscal 2025.
View full Heron Therapeutics company overview| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 73.31% | +0.09 pp |
| 2024 | 2024-12-31 | 73.21% | +24.46 pp |
| 2023 | 2023-12-31 | 48.75% | −0.28 pp |
| 2022 | 2022-12-31 | 49.04% | — |
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 69.28% | −4.23 pp |
| Q1 2026 | 2026-03-31 | 69.35% | −8.91 pp |
| Q4 2025 | 2025-12-31 | 72.61% | −2.31 pp |
| Q3 2025 | 2025-09-30 | 68.82% | −2.35 pp |
| Q2 2025 | 2025-06-30 | 73.50% | +2.70 pp |
| Q1 2025 | 2025-03-31 | 78.26% | +2.62 pp |
| Q4 2024 | 2024-12-31 | 74.92% | +3.80 pp |
| Q3 2024 | 2024-09-30 | 71.17% | +29.10 pp |
| Q2 2024 | 2024-06-30 | 70.80% | +34.27 pp |
| Q1 2024 | 2024-03-31 | 75.64% | +32.55 pp |
| Q4 2023 | 2023-12-31 | 71.12% | +26.54 pp |
| Q3 2023 | 2023-09-30 | 42.08% | — |
| Q2 2023 | 2023-06-30 | 36.53% | — |
| Q1 2023 | 2023-03-31 | 43.09% | — |
| Q3 2022 | 2022-09-30 | 44.58% | — |
Across the available reported history, Heron Therapeutics's gross margin increased from 73.21% to 73.31%, a change of +0.09 percentage points. The latest reported quarter, Q2 2026, shows 69.28%.
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Heron Therapeutics filings at SEC.gov ↗